US EditionPublished • loading... • Updated
China’s Biotech Deals Evolve: Beyond Licensing Amid ‘Crazy’ Valuations
Summary by Digital Phablet
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
China’s Biotech Deals Evolve: Beyond Licensing Amid ‘Crazy’ Valuations
China’s biotech sector is rapidly transitioning from relying on product exports to becoming a leader in value exports, transforming cross-border deal-making, valuation approaches, and long-term international strategies, according to industry experts attending the International Biopharma Industry Week and the 12th BioCentury-BayHelix China Healthcare Summit in Shanghai. Historically, licensing out products has been the primary route for Chinese b…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
